Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886718 | 0.90 | HPGD (0.58) | SMN1; SMN2L3MBTL1KDM4EUSP2LMNA | |
| SCHEMBL19981514 | 0.86 | MAPT (0.50) | SMN1; SMN2L3MBTL1KDM4EGAAHTT | |
| SCHEMBL10748367 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2L3MBTL1KDM4EGAAHTT | |
| SCHEMBL3635025 | 0.82 | KDM4E (0.60) | SMN1; SMN2L3MBTL1KDM4EGAANPC1 | |
| SCHEMBL27737313 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL23657165 | 0.80 | CYP1A2 (0.58) | SMN1; SMN2L3MBTL1HTTNPC1RAB9A | |
| SCHEMBL9051688 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL1KDM4EGAAHTT | |
| SCHEMBL10750240 | 0.78 | ADAM17 (0.48) | SMN1; SMN2L3MBTL1KDM4EHTTNPC1 | |
| SCHEMBL1520344 | 0.77 | SMN1; SMN2 (0.71) | SMN1; SMN2L3MBTL1KDM4EGAAHTT | |
| SCHEMBL7058892 | 0.77 | SMN1; SMN2 (0.80) | SMN1; SMN2L3MBTL1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118119409-A | Pharmaceutical composition for treating and/or preventing cancer | 东丽株式会社 | 2024-05-31 | — | — | CN | disclosed |
| EP-2357006-B1 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2353611-B1 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8906376-B2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| WO-2014086952-A1 | CONJUGATES OF THE B-SUBUNIT OF SHIGA TOXIN FOR ANTICANCER THERAPIES | INSTITUT CURIE (FR) | 2014-06-12 | — | — | WO | disclosed |
| EP-2740493-A1 | Conjugates of the B-subunit of Shiga toxin for anticancer therapies | Institut Curie (FR) | 2014-06-11 | — | — | EP | disclosed |
| EP-1545613-B9 | AURISTATIN CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS INC (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2357006-A2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | Seattle Genetics, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2353611-A2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | Seattle Genetics, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-1545613-B1 | AURISTATIN CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20040157782-A1 | Pentapeptide compounds and uses related thereto | SEAGEN INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1390393-A2 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | Seattle Genetics, Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2004010957-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | SEATTLE GENETICS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| WO-2002088172-A2 | PENTAPEPTIDE COMPOUNDS AND USES RELATED THERETO | SEATTLE GENETICS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-6057451-A | AMINOTHIAZOLE DERIVATIVES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-05-02 | — | — | US | disclosed |
| CN-1207094-A | Phenyl thiazole derivatives with anti herpes virus properties | BOEHRINGER INGELHEIM PHARMA (US) | 1999-02-03 | — | — | CN | disclosed |
| EP-0871619-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997024343-A1 | PHENYL THIAZOLE DERIVATIVES WITH ANTI HERPES VIRUS PROPERTIES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| US-4307106-A | IMMUNO-REGULANT EFFECT, TREATING RHEUMATOID ARTHRITIS | PFIZER INC. (US) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083263-A1 | Pentapeptide compounds and uses related thereto | NGLY1, VIP, DNPEP | SMN1; SMN2 3900/4885L3MBTL1 640/4885KDM4E 4594/4885 |
| US-20040157782-A1 | Pentapeptide compounds and uses related thereto | VIP, NGLY1, DNPEP | SMN1; SMN2 2986/4885L3MBTL1 939/4885KDM4E 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.